Kornimate/medical-research-clean huggingface dataset:
dexmedetomidine versus triamcinolone treatment of carpal tunnel syndrome

Conditions: Chronic Pain; Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome (cts) is a common mononeuropathy due to entrapment of the median nerve in the carpal tunnel. a lot of modaleties are available for treatment of mild to moderate cts.

carpal tunnel syndrome (cts) is a common mononeuropathy due to entrapment of the median nerve in the carpal tunnel. a lot of modaleties are available for treatment of mild to moderate cts. in case of failed conservative oral therapey, local hydro-dessction of the median nerve can be done with saline alone. local anethetics, steroids, hyalase,and ozone have been utilized to augment the symptoms reliefe. dexmeditomidine (dex) has been studied as adjuvant for nerve block to aumnet the pain reliefe. recently, it has been discovered that dex can offer some antinflammatory effects when injected in the perineural area. upon such discovery, the goal of this study has been built.

Eligibility criteria:
inclusion criteria: * adult patients * complaining of carpal tunnel syndrome of 3 month duration or more * diagnosed axonal neuropathy using electrodiagnosis , nerve conduction study exclusion criteria: * patient refusal * infection at the site of intervention * allergy to utilized drugs * diabetic * previous surgery in the site of injection * previous injection in the targeted site within the last year
evaluation of risk factors of sleep quality in intensive care unit

Conditions: Sleep Disorders; Delirium

Summary: the aim of this study was to investigate the relationship between sleep disturbances and delirium in surgical icu patients. the study set up to test the hypothesis that the occurrence of delirium is associated to the alteration of sleep quality and quantity observed in the critically ill patients.

sleep disorders are an important clinical entity affecting outcome in respiratory, cardiovascular, metabolic and psychiatric disorders and exacting a potentially significant toll on patients at both a personal and socio-economic level.delirium is a common organ dysfunction in the critically ill patients characterized by an acute onset of impaired cognitive function \[ref\] associated with prolonged icu and hospital stay, nosocomial pneumonia, and death.

Eligibility criteria:
inclusion criteria: * adult, postsurgical patients who needed mechanical ventilation for more than 48 hr admitted to the general icu exclusion criteria: * defined a priori * were history of chronic dementia, psychosis, mental retardation, stroke syndrome or other primary neurologic disease * patient refusal to participate * alcohol and drug abuse.

Keywords: sleep icu delirium post surgical ventilated patients icu patients
lung ultrasound for physiotherapy in hospitalized patients with respiratory complications

Conditions: Respiratory Complication

Summary: this study aims to evaluate the relevance of using point-of-care lung ultrasound (lus) in modifying the physiotherapist's treatment plan for patients hospitalized in a general ward.

hospitalized patients often confront respiratory issues stemming from diverse causes, such as pneumonia. physiotherapists rely on a range of clinical and imaging data to inform their treatment decisions. yet, they face challenges due to the absence of readily accessible, sensitive, specific, and reliable measurements to tailor the most effective physical therapeutic interventions based on individual clinical scenarios. point-of-care lung ultrasound (lus) holds promise in addressing these existing gaps. this study aims to evaluate the impact of integrating lus into clinical practice by comparing physiotherapists' initial clinical assessments and treatment plans with those made after incorporating lus findings in patients admitted to a general ward.

Eligibility criteria:
inclusion criteria: * hospitalization in a general ward * acute respiratory symptoms (\< 48h) * chest x-ray available within 24h before or after the use of lus exclusion criteria: * any conditions precluding the use of lus (thoracic skin lesions, thoracic bandage, subcutaneous emphysema) * inability to understand instructions due to cognitive impairment or due to language barrier
myofascial release techniques in football players

Conditions: Fasciae (Anatomy)--Inflammation

Summary: fascial tissue ensures optimal function and mobility by providing gliding and force transfer during movement. however, fascial order can be disrupted in cases such as overuse and trauma. therefore, treatment of fascial tissue is important. therefore, this study aimed to investigate the effects of different myofascial release techniques on jumping performance, flexibility, balance, and proprioception in amateur football players.

fascial tissue ensures optimal function by providing gliding and force transfer during movement. it is also associated with an increase in functional capacity by providing flexibility. however, excessive exercise, incorrect movements, and excessive load on the tissue cause dysfunctions in the fascial tissue, leading to myofascial limitations. elimination of these limitations is important for the maintenance of optimal function. fascia also provides sensory transmission as a proprioceptive organ. myofascial limitations also cause problems in sensory organization, leading to injuries and injuries. for this reason, a decrease in flexibility, balance, and sports functions can be observed. various methods are used to eliminate this myofascial limitation, and there is an increasing demand for myofascial release techniques in many areas daily. the effects of different myofascial release techniques have been examined in the literature in various disease groups and sports injuries, and their effects on joint range of motion, pain, and flexibility have been shown. however, since there are different release techniques, information on which method is more effective or the optimal usage period is unclear. therefore, this study aimed to investigate the effects of different myofascial release techniques applied with graston and foam roller on jumping performance, flexibility, balance, and proprioception in amateur football players.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-35 * being able to communicate in turkish * being willing to participate in the study. * being a licensed football player exclusion criteria: * those with a body mass index of 30 kg/m² or higher * those with a history of lower extremity surgery in the last 6 months * those with cardiac, musculoskeletal, vestibular, and neurological problems * those with mental, perceptual problems (mini-mental test score \<24)
synergic control of posture in peripheral neuropathies' patients

Conditions: Peripheral Neuropathies

Summary: this is a multicenter observational study aimed to characterize multi-muscle synergy organization in relation to postural stability in individuals with peripheral neuropathies (pn) compared to healthy age-matched subjects and to assess the effectiveness of a rehabilitation program driven by multi-muscle synergy organization.

this is a multicenter observational study of peripheral neuropathies patients aiming at characterizing multi-muscle synergy and at assessing the effectiveness of a rehabilitation program driven by multi-muscle synergy organization. the study can be divided in two phases: phase 1 will included peripheral neuropathies patients and healthy age-matched subjects. peripheral neuropathies patients will be assessed with: * neurological assessment formalized via total neuropathy score-clinical version (tnsc©) * nerve conduction studies * impact of pn on patients' quality of life using short form health survey 36 (sf-36) * functional status using functional independence measure (fim) peripheral neuropathies patients and healthy age-matched subjects will receive a postural evaluation recording during three different postural tasks (quiet standing, voluntary sway and shoulder flexion): * centre of pressure (cop) displacement of force platform; * surface muscle activation using electromyography (emg) of 13 muscle on the right side of the body (tibialis anterior, soleus,gastrocnemius lateralis-medialis, biceps femoris, semitendinosus, rectus femoris, vastus lateralis and medialis, tensor fasciae latae, lumbar and thoracic erector spinae and rectus abdominis). phase 2 will included only peripheral neuropathies patients. participants will be assessed at baseline, after a 20 session 2-3/w program of physical therapy and at a follow up of 3 months. the evaluations of the first phase will be implemented with evaluation of mobility and balance using six minute walking test (6mwt), mini balance evaluation system test (minibestest) and timed up and go test (tug).

Eligibility criteria:
inclusion criteria: * subject suffering from peripheral neuropathy with a tnsc© score more than 4 * male and female subjects who are 18 years of age or older exclusion criteria: * orthopedic or neurologic comorbidities that can influence postural control a control group of healthy subjects with the same demographic features of peripheral neuropathy patients wil be also included.
a study to understand the safety of the 20vpnc vaccine in healthy chinese adults, children, and infant

Conditions: Pneumococcal Disease

Summary: the purpose of this study is to learn about the safety of the 20-valent pneumococcal conjugate vaccine (20vpnc). this vaccine will be given as per the age-specific dosing schedules among healthy adults, children and infants in china. this study is seeking healthy participants of 5 specific age groups: * group 1: adults ≥18 to \<50 years of age * group 2: children ≥2 to \<6 years of age * group 3: children ≥12 months to \<2 years of age * group 4: infants ≥7 to \<12 months of age * group 5: infants ≥42 to ≤98 days of age all participants in this study will receive 20vpnc as per the age-specific dosing schedules: * group 1: participants will receive 1 dose of 20vpnc. * group 2: participants will receive 1 dose of 20vpnc. * group 3: participants will receive 2 doses of 20vpnc. dose 2 will be given 56 to 70 days after dose 1. * group 4: participants will receive 3 doses of 20vpnc. dose 2 will be given 28 to 56 days after dose 1, and dose 3 will be given at 365 to \<455 days of age and at least 56 days after dose 2. * group 5: participants will receive 4 doses of 20vpnc. dose 2 will be given 42 to 63 days after dose 1, and dose 3 should be given 42 to 63 days after dose 2, and dose 4 should be given at 365 to \<455 days of age. the study will look at the experiences of people receiving the study vaccine. this will help decide if the study vaccine is safe. the total duration of taking part in the study from each group is: * participants in group 1 and group 2 will take part for about 6 months, with 6 visits. * participants in group 3 will take part for about 8 months, with 9 visits. * participants in group 4 will take part for about 12 months, with 8 visits. * participants in group 5 will take part for about 16 to 19 months, with 11 visits.


Eligibility criteria:
key inclusion criteria: * male or female participants: * adults ≥18 to \<50 years of age * children ≥2 to \<6 years of age * children ≥12 months to \<2 years of age * infants ≥7 to \<12 months of age * infants ≥42 to ≤98 days of age * healthy participants determined by clinical assessment and clinical judgment, to be eligible for the study. key exclusion criteria: * history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention, or any diphtheria toxoid-containing vaccine. * history of microbiologically proven invasive disease caused by s pneumoniae. * congenital, functional, or surgical asplenia. * previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt during study participation. * determined as not eligible by the investigator based on the participant's past and present health condition(s), medication(s) and treatment(s). please refer to the study contact for further eligibility details.
the induction of il-6 by nf-kb in pbmc in osa

Conditions: Sleep Apnea, Obstructive

Summary: aim of study: 1. to compare the level of il-6 mrna expression in peripheral blood monocytes between normal subjects and patients with osas 2. to compare the activation of nf-b in peripheral blood monocytes between control subjects and patients with osas; check the correlation between level of l-6 mrna expression and activation of nf-kb 3. to determine the effect of cpap on the activation of nf-kb and il-6 in peripheral blood monocytes in patients with moderate -severe osas

obstructive sleep apnea syndrome (osas) has emerged in recent years as an important risk factor for cardiovascular morbidity. the mechanisms responsible for developments of cardiovascular sequelae in patients with osa include hypoxia, hypercapnia, exaggerated negative intrathoracic pressure and bursts of sympathetic activity provoking surges in blood pressure and heart rate. meanwhile, increase of inflammatory mediators, which included c-reactive protein (crp), oxidative stress, adhesion molecules, vascular endothelial growth factor (vegf) and proinflammatory cytokines (interleukin (il) -1, il-2, il-6, il-8, il-10 and tumor necrotic factor- (tnf-)), also involve in the development of cardiovascular disease in patients with osas. according to our preliminary study, serum levels of il-6 and crp were higher in patients with osas than control subjects and levels of both il-6 and crp were highly correlated with the lowest pulse oxygen saturation. hypoxia triggered the production of il-6 through the induction of nfb, which was demonstrated in ischemic heart disease and pancreatitis. however, this mechanism has not been prooved in osas. therefore, we conduct this study to prove our hypothesis (1) the mrna expression of il-6 in peripheral blood monocytes was significantly higher in patients with osas than control subjects (2) the activation of nf-k b in peripheral blood monocytes was more significant in patients with osas than control subjects, and the level of nf- kb activation is associated with the level of il-6 mrna expression (3) cpap therapy could lower both the activation of nf-kb and il-6 mrna expression in patients with moderate-severe osas.

Eligibility criteria:
inclusion criteria: * severe obstructive sleep apnea (ahi\>=30 /hr) male older than 18 y/o exclusion criteria: * refuse participate, chronic lung disease active infection neurologic event
evidence-based tele-emergency network grant program

Conditions: Critical Illness

Summary: the purpose of this study is to determine the impact of an existing tele-emergency care network on quality of care, appropriateness of care utilization, patient safety (medication errors), and cost effectiveness compared to telephone consultations from a healthcare system prospective.

the investigators will use a novel cluster randomized unbalanced crossover trial design. when a new site is enrolled, the first approximately 6 months of the project will be a "ramp-up" period during which the protocol will be re-reviewed during a site visit to the participating eds and random block assignments will be generated and delivered. the last 6 months will be reserved for data analysis, study closeout, and manuscript preparation. an intervening 2-year period will be divided into 4 six-month calendar time periods for carrying out the protocol and data collection. for each 6-month period, each ed will have a randomized treatment assignment for pediatric emergency and critical care consultations ("m" for telemedicine and "p" for telephone.) participating eds (the unit of randomization) will be stratified into two strata by size of ed and geographical location. eds will then be randomized within-strata to one of the four unbalanced (3:1) crossover treatment assignment sequences, each consisting of a 6-month period: pmmm, mpmm, mmpm, or mmmp. during these assigned periods, the type of consultation being assigned will be strongly encouraged, but deviating from protocol (i.e., using telephone consultation when randomized to telemedicine, or the vice-versa) will be allowed as needed by the physicians. data will be collected and abstracted through retrospective chart review.

Eligibility criteria:
inclusion criteria: * children younger than or equal to 14 years of age at the time of their ed visit. exclusion criteria: * children evaluated at the ed for non-medical reasons such as elective surgeries and social reasons (i.e., cases of possible endangerment) and other non-medical reasons. * children evaluated at the ed preoperatively, for elective surgical procedures. * children transferred to the ed from another hospital ed. * children transiently "held" in the ed in the process of a direct admission to the ward.
metoprolol xr in heart failure with normal ejection fraction

Conditions: Diastolic Heart Failure

Summary: in contrast to the treatment of hf with reduced ef, information to guide the pharmacological therapy of patients with hfnef are lacking and there is no evidence based treatment for patients with hfnef. thus, present treatment strategies for hfnef are largely based on assumptions regarding its pathophysiological mechanisms and on extrapolations from proven strategies used in systolic hf. till now, no study enlightens the efficacy and safety of beta blockers in hfnef in a randomised controlled manner although the role of beta blockers in hf with impaired systolic function has been sufficiently time tested leading to their therapeutic approval in that condition. keeping in view the small reported benefit of beta blockers in hfnef as mentioned above, there is a need to provide a conclusive proof of their role in this condition as well. hence, investigators planned to test the efficacy and safety of metoprolol cr in patients with hfnef in a randomised double blind placebo controlled trial.


Eligibility criteria:
inclusion criteria: * age 18 years and above of either sex * presence of new york heart association functional class ii-iv of at least 4 weeks' duration * lvef ≥ 50% in a nondilated lv (lv end-diastolic volume \< 97 ml/m2 measured by echocardiography) * echocardiographic evidence of lv diastolic dysfunction * willing to give written informed consent exclusion criteria: * clinically unstable as defined by any change in diuretic dose in the month prior to enrolment. * significant valvular heart disease, pericardial disease, hypertrophic or restrictive cardiomyopathy * unstable angina or mi within the past 4 weeks. * alternative probable cause of the patient's symptoms (e.g.significant pulmonary disease); * any previous left ventricular ejection fraction below 40% * other systemic disease limiting life expectancy to less than 3 years * any contraindication to metoprolol use (heart rate less than 45 beats per minute, heart block greater than first-degree i.e. pr interval ≥ 0.24 second, systolic blood pressure \<100 mm hg, asthma) * conditions associated with alteration in serum levels of procollagen type i e.g. alcoholic liver disease, metabolic bone disease, hyperthyroidism * current participation (including prior 30 days) in any other therapeutic trial * any condition that, in the opinion of the investigator, may prevent the participant from adhering to the trial protocol

Keywords: heart failure, metoprolol, diastolic dysfunction
dose-ranging efficacy study of topical neosh101 to treat male pattern hair loss

Conditions: Androgenetic Alopecia

Summary: the purpose of this study is to evaluate the safety and efficacy of three doses of topical neosh101 applied once-daily (qd) for 16 weeks in men with thinning hair in the top and center of the scalp (norwood/hamilton grades iii-iv androgenetic alopecia). four equally sized treatment groups (35 men each) will receive either neosh101 0.5%, neosh101 1.0%, neosh101 2.0% or placebo. a 12-week observation period will follow the treatment period.


Eligibility criteria:
inclusion criteria: * men, aged 18 to 49 years, in general good health * norwood/hamilton grades iii - iv androgenetic alopecia, with thinning hair in the vertex area exclusion criteria: * concomitant dermatologic or medical condition(s) which may interfere with the investigator's ability to evaluate the subject's response to the study drug * treatment with a systemic or locally acting medication which may interfere with the study objectives, such as minoxidil treatment in the 6 months prior to study day 1, finasteride treatment in the 12 months prior to study day 1, or treatment with other investigational hair growth products in the 6 months prior to study day 1

Keywords: androgenetic alopecia male pattern hair loss male pattern baldness androgenetic alopecia or male pattern hair loss
patient experiences in rheumatology

Conditions: Rheumatic Disease

Summary: information was entered by mistake by a research assistant. study never went beyond the initial discussion phase.


Eligibility criteria:
all adult patients who have an appointment scheduled at the rheumatology clinic at good samaritan hospital, can speak and read english and are willing and capable of providing informed consent are eligible to participate. all fellows in the rheumatology fellowship training program will participate.

Keywords: communication patient experience fellowship training
registry of celution device for the processing of adipose derived regenerative cells (adrcs) to treat osteoarthritis

Conditions: Osteoarthritis

Summary: this registry study will compile information from patients that are scheduled to receive or have received adipose derived regenerative cells (adrcs) prepared by the celution device to treat osteoarthritis in the knee.


Eligibility criteria:
inclusion criteria: * males or females \> 18 years of age * diagnosis of osteoarthritis in one or both knees with kellgren lawrence grade ≥ 2 at x-ray evaluation or mri findings of degenerative changes * pain with or without swelling in the affected area for \>4 months exclusion criteria: * know spine or disc disease or symptomatic nerve impingement contributing to pain in the affected limb * history of documented nerve damage in the affected limb * pregnant or lactating status. pregnancy as determined by a positive pregnancy test prior to procedure.

Keywords: osteoarthritis, knee